Drugs / Ritobegron
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02256722 | Oct → Nov 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02256735 | Aug → Dec 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02259907 | May 2003 → Feb 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00742833 | — | overactive bladder | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01004315 | — | overactive bladder | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01003405 | — | overactive bladder | Kissei Pharmaceutical Co., Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ritobegron | “Study to investigate the effect of Ritobegron CL (KUC 7483 CL) on the QT/QTc interval of the ECG in comparison to placebo and moxifloxacin” NCT02256735 ↗1“a single oral dose of 320 mg ritobegron administered alone or with a pre- and comedication with bisoprolol, propranolol and acipimox” NCT02256722 ↗ |
| Known as | KUC 7483 | “Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (40 to 400 mg) of KUC-7483 Tablets” NCT02259907 ↗4“Study to investigate safety, tolerability and pharmacokinetics of KUC 7483” NCT02259907 ↗ |
| Known as | KUC 7483 CL | “Study to investigate the effect of Ritobegron CL (KUC 7483 CL) on the QT/QTc interval of the ECG in comparison to placebo and moxifloxacin” NCT02256735 ↗ |
| Known as | Ritobegron Cl | “Study to investigate the effect of Ritobegron CL (KUC 7483 CL) on the QT/QTc interval of the ECG in comparison to placebo and moxifloxacin” NCT02256735 ↗ |
| Action | Activate | “Beta-3 adrenergic receptor agonist” CHEMBL2107773 ↗ |
| Modality | Small molecule | — CHEMBL2107773 ↗ |
| Route | Oral | “a single oral dose of 320 mg ritobegron administered alone” NCT02256722 ↗ |
| Target | ADRB3 | “Beta-3 adrenergic receptor agonist” CHEMBL2107773 ↗ |